-
The chief growth officer of Corcept Therapeutics bought 20,000 shares of the biotech for $703,656 on Tuesday.
-
The transaction was executed as a direct open-market sale of possibility shares; no oblique entities had been concerned.
-
The chief reported holding inventory choices underlying 250,000 shares after the transaction.
-
These 10 shares might mint the subsequent wave of millionaires ›
On Tuesday, William Guyer, the chief growth officer of Corcept Therapeutics (NASDAQ:CORT), exercised and instantly bought 20,000 shares by way of open-market transactions totaling roughly $703,656, based on an SEC Kind 4 submitting.
|
Metric
|
Worth
|
|
Shares bought (direct)
|
20,000
|
|
Transaction worth
|
$703,656
|
|
Submit-transaction shares (direct)
|
1,235
|
|
Submit-transaction worth (direct possession)
|
$44,188.30
|
-
What’s the by-product context of this transaction?
This occasion concerned the train of 20,000 inventory choices instantly adopted by sale of the ensuing frequent shares on the open market, with no oblique automobiles or gifting parts.
-
How did this transaction have an effect on William Guyer’s direct possession?
Direct frequent inventory holdings declined from 21,235 shares to 1,235 shares, a discount of 94.18% of his direct fairness stake; nevertheless, he additionally reported holding inventory choices underlying 250,000 shares after the transaction.
-
What’s the remaining fairness publicity after this transaction?
After this sale, Guyer retains 1,235 straight held shares valued at roughly $44,188.
|
Metric
|
Worth
|
|
Worth (as of market shut Tuesday)
|
$35.18
|
|
Market capitalization
|
$3.94 billion
|
|
Income (TTM)
|
$741.17 million
|
|
Web revenue (TTM)
|
$106.11 million
|
* 1-year efficiency is calculated utilizing Tuesday because the reference date.
-
Corcept Therapeutics generates income primarily from Korlym, an FDA-approved remedy for Cushing’s syndrome, and is advancing a pipeline of selective cortisol modulators focusing on metabolic, oncologic, and neuropsychiatric issues.
-
The corporate operates a drug discovery, growth, and commercialization mannequin, monetizing proprietary therapies by way of direct gross sales and ongoing scientific growth of recent indications.
-
Its main clients embody healthcare suppliers and specialists treating sufferers with endocrine and oncology issues in the USA.
Corcept Therapeutics is a mid-cap biotechnology firm centered on the event and commercialization of therapies for extreme endocrine and oncologic situations. The corporate leverages experience in cortisol modulation to handle unmet medical wants, supported by a rising portfolio of proprietary drug candidates. Corcept’s established market presence in Cushing’s syndrome and its advancing scientific pipeline present a basis for continued development and aggressive differentiation in specialised therapeutic markets.
Corcept’s inventory had been one of many market’s quiet winners for a lot of the previous yr earlier than a pointy collapse on Dec. 31, following the FDA’s full response letter for relacorilant; nevertheless, the Kind 4 exhibits the transaction stemmed from an possibility train, not a discount in long-term publicity. Whereas Guyer’s direct frequent inventory place fell sharply, his remaining fairness publicity is overwhelmingly by-product, with choices representing much more upside sensitivity than the small variety of shares retained outright. That construction suggests portfolio administration somewhat than a shift in outlook.
Essentially, Corcept entered the regulatory setback from a place of power. Third-quarter income rose to $207.6 million, up from $182.5 million a yr earlier, pushed by continued development in Korlym prescriptions. Administration reaffirmed full-year income steering of $800 million to $850 million and ended the quarter with $524 million in money and investments, offering stability sheet flexibility even amid scientific uncertainty.
In the end, options-related promoting amid a regulatory shock shouldn’t be conflated with a weakening core enterprise. The actual sign stays scientific execution and the trail ahead for relacorilant, not a single administrative liquidity occasion.
Kind 4: A required SEC submitting disclosing insider trades of firm securities by officers, administrators, or main shareholders.
Exercised (inventory choices): The act of changing inventory choices into precise firm shares, often by paying a set value.
Open-market transaction: Shopping for or promoting securities on a public change somewhat than by way of non-public or inner firm preparations.
Direct holdings: Shares owned personally by a person, not by way of trusts, funds, or different entities.
Choice shares: Shares obtained by exercising inventory choices, sometimes granted as a part of worker compensation.
Oblique entities: Organizations or accounts, comparable to trusts or funds, used to carry shares on behalf of a person.
Gifting parts: The switch of shares to a different occasion as a present, somewhat than by way of sale or buy.
Fairness publicity: The worth or proportion of an individual’s funding in an organization’s shares.
Excellent shares: Whole shares of an organization which are at the moment owned by all shareholders, together with restricted shares.
Medical pipeline: An organization’s portfolio of drug candidates in varied phases of analysis and growth.
Cortisol modulator: A drug designed to change the physique’s response to the hormone cortisol, typically for therapeutic functions.
TTM: The 12-month interval ending with the newest quarterly report.
Ever really feel such as you missed the boat in shopping for essentially the most profitable shares? You then’ll need to hear this.
On uncommon events, our knowledgeable workforce of analysts points a “Double Down” inventory suggestion for firms that they suppose are about to pop. If you happen to’re anxious you’ve already missed your likelihood to speculate, now could be the perfect time to purchase earlier than it’s too late. And the numbers converse for themselves:
-
Nvidia: in case you invested $1,000 after we doubled down in 2009, you’d have $479,476!*
-
Apple: in case you invested $1,000 after we doubled down in 2008, you’d have $49,342!*
-
Netflix: in case you invested $1,000 after we doubled down in 2004, you’d have $482,451!*
Proper now, we’re issuing “Double Down” alerts for 3 unimaginable firms, obtainable if you be part of Inventory Advisor, and there might not be one other likelihood like this anytime quickly.
See the three shares »
*Inventory Advisor returns as of January 5, 2026
Jonathan Ponciano has no place in any of the shares talked about. The Motley Idiot has positions in and recommends Corcept Therapeutics. The Motley Idiot has a disclosure coverage.
Corcept Insider Transaction Defined After Shares Tumble 50% in One Day was initially revealed by The Motley Idiot
